Remus Pharmaceuticals share news and announcements
NSE: REMUSPharmaceuticals & Biotechnology
Last close ₹880.60down ₹20.60 (2.29%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹901.20.
52-week range of traded prices to 23 Oct 2026
₹580.00Low, 9 Mar 2026₹1,039.00High, 15 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹1,038 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 20 May 2026
- 28.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 20 May 2026
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 20 May 2026
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 20 May 2026
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 May 2026
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 2,80085.7% delivered
Remus Pharmaceuticals share news and announcements
142 announcements, routine notices left out, newest first. Page 2 of 3.
May 2025
17 May · General Updates
17 May · General Updates
17 May · General Updates
17 May · Board meeting
14 May · Analysts
Apr 2025
Feb 2025
27 Feb · Board meeting
Jan 2025
Dec 2024
Nov 2024
11 Nov · Analysts
9 Nov · Related Party Transactions
5 Nov · Corporate action
Sep 2024
Aug 2024
14 Aug · Board meeting
Jun 2024
May 2024
23 May · Corporate action
16 May · Related Party Transactions
16 May · Board meeting
Apr 2024
23 Apr · Corporate action
23 Apr · Board meeting
16 Apr · Board meeting
Not held on this date